Ninety One SA PTY Ltd Purchases New Position in Edwards Lifesciences Co. (NYSE:EW)

Ninety One SA PTY Ltd purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,993 shares of the medical research company’s stock, valued at approximately $686,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Ninety One UK Ltd increased its stake in shares of Edwards Lifesciences by 2,740.5% in the 4th quarter. Ninety One UK Ltd now owns 498,029 shares of the medical research company’s stock valued at $37,975,000 after purchasing an additional 480,496 shares in the last quarter. Twin Capital Management Inc. increased its stake in shares of Edwards Lifesciences by 35.3% in the 4th quarter. Twin Capital Management Inc. now owns 9,699 shares of the medical research company’s stock valued at $740,000 after purchasing an additional 2,532 shares in the last quarter. Groesbeck Investment Management Corp NJ purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $206,000. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Edwards Lifesciences by 131.7% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 17,237 shares of the medical research company’s stock valued at $1,314,000 after purchasing an additional 9,797 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in Edwards Lifesciences by 8.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 66,570 shares of the medical research company’s stock worth $5,076,000 after buying an additional 5,375 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of several research reports. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Mizuho upped their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Finally, Oppenheimer upped their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Stock Down 0.8 %

NYSE:EW traded down $0.73 during trading hours on Thursday, hitting $86.51. The company’s stock had a trading volume of 1,902,058 shares, compared to its average volume of 3,848,036. The stock has a market capitalization of $52.07 billion, a P/E ratio of 37.93, a price-to-earnings-growth ratio of 4.46 and a beta of 1.05. The stock has a fifty day moving average of $90.12 and a 200-day moving average of $78.14. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.64 earnings per share. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.